These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

674 related articles for article (PubMed ID: 29479938)

  • 21. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change.
    Ertas R; Ozyurt K; Atasoy M; Hawro T; Maurer M
    Allergy; 2018 Mar; 73(3):705-712. PubMed ID: 29083482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Omalizumab in elderly patients with chronic spontaneous urticaria: An Italian real-life experience.
    Nettis E; Cegolon L; Di Leo E; Canonica WG; Detoraki A;
    Ann Allergy Asthma Immunol; 2018 Mar; 120(3):318-323. PubMed ID: 29508719
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy of omalizumab treatment in chronic spontaneous urticaria is associated with basophil phenotypes.
    Johal KJ; Chichester KL; Oliver ET; Devine KC; Bieneman AP; Schroeder JT; MacGlashan DW; Saini SS
    J Allergy Clin Immunol; 2021 Jun; 147(6):2271-2280.e8. PubMed ID: 33713769
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Omalizumab: what benefits should we expect?
    Giménez-Arnau A; Velasco M; Armario Hita JC; Labrador-Horrillo M; Silvestre Salvador JF
    Eur J Dermatol; 2016 Aug; 26(4):340-4. PubMed ID: 27210073
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-TPO IgG/Total IgE Ratio: Biomarker for Omalizumab Response Prediction in Chronic Spontaneous Urticaria.
    Brás R; Esteves Caldeira L; Bernardino A; Costa C
    Int Arch Allergy Immunol; 2023; 184(9):866-869. PubMed ID: 37557083
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Omalizumab Treatment Response in Patients with Chronic Spontaneous Urticaria and Symptomatic Dermographism: A Single-Center Retrospective Study.
    Cakmak ME; Yeğit OO; Öztop N
    Int Arch Allergy Immunol; 2023; 184(3):236-242. PubMed ID: 36543155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predicting Chronic Spontaneous Urticaria Symptom Return After Omalizumab Treatment Discontinuation: Exploratory Analysis.
    Ferrer M; Giménez-Arnau A; Saldana D; Janssens N; Balp MM; Khalil S; Risson V
    J Allergy Clin Immunol Pract; 2018; 6(4):1191-1197.e5. PubMed ID: 29655772
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials.
    Zhao ZT; Ji CM; Yu WJ; Meng L; Hawro T; Wei JF; Maurer M
    J Allergy Clin Immunol; 2016 Jun; 137(6):1742-1750.e4. PubMed ID: 27040372
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chronic urticaria treatment patterns and changes in quality of life: AWARE study 2-year results.
    Maurer M; Giménez-Arnau A; Ensina LF; Chu CY; Jaumont X; Tassinari P
    World Allergy Organ J; 2020 Sep; 13(9):100460. PubMed ID: 32983330
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-life data on the effectiveness and safety of omalizumab in monotherapy or combined for chronic spontaneous urticaria: a retrospective cohort study.
    Salman A; Ergun T; Gimenez-Arnau AM
    J Dermatolog Treat; 2020 Mar; 31(2):204-209. PubMed ID: 30821591
    [No Abstract]   [Full Text] [Related]  

  • 31. Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1-antihistamine treatment: results of the phase IV open-label SUNRISE study.
    Bérard F; Ferrier Le Bouedec MC; Bouillet L; Reguiai Z; Barbaud A; Cambazard F; Milpied B; Pelvet B; Kasujee I; Gharbi H; Lacour JP
    Br J Dermatol; 2019 Jan; 180(1):56-66. PubMed ID: 29927483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria.
    Kaplan A; Ferrer M; Bernstein JA; Antonova E; Trzaskoma B; Raimundo K; Rosén K; Omachi TA; Khalil S; Zazzali JL
    J Allergy Clin Immunol; 2016 Feb; 137(2):474-81. PubMed ID: 26483177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Omalizumab substantially improves dermatology-related quality of life in patients with chronic spontaneous urticaria.
    Finlay AY; Kaplan AP; Beck LA; Antonova EN; Balp MM; Zazzali J; Khalil S; Maurer M
    J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1715-1721. PubMed ID: 28573683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of clinical factors as possible predictors of response to omalizumab and relapse after treatment discontinuation in chronic spontaneous urticaria.
    Foti C; Romita P; Ambrogio F; Fanelli M; Panebianco R; Vena GA; Cassano N; Ragusa M; Giuffrida R; Papaianni V; Borgia F; Cannavò SP; Guarneri F
    Dermatol Ther; 2022 Feb; 35(2):e15248. PubMed ID: 34877757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Omalizumab therapy for treatment of recalcitrant chronic spontaneous urticaria in an Asian population.
    Kulthanan K; Tuchinda P; Chularojanamontri L; Likitwattananurak C; Ungaksornpairote C
    J Dermatolog Treat; 2017 Mar; 28(2):160-165. PubMed ID: 27388043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of 'real-world' evidence.
    Bernstein JA; Kavati A; Tharp MD; Ortiz B; MacDonald K; Denhaerynck K; Abraham I
    Expert Opin Biol Ther; 2018 Apr; 18(4):425-448. PubMed ID: 29431518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin.
    Metz M; Staubach P; Bauer A; Brehler R; Gericke J; Kangas M; Ashton-Chess J; Jarvis P; Georgiou P; Canvin J; Hillenbrand R; Erpenbeck VJ; Maurer M
    Theranostics; 2017; 7(5):1266-1276. PubMed ID: 28435464
    [No Abstract]   [Full Text] [Related]  

  • 38. A retrospective analysis omalizumab treatment patterns in patients with chronic spontaneous urticaria: a real-world study in Belgium.
    Lapeere H; Baeck M; Stockman A; Sabato V; Grosber M; Moutschen M; Lambert J; Vandebuerie L; de Montjoye L; Rabijns H; Allewaert K; Schrijvers R
    J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):127-134. PubMed ID: 31099916
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials.
    Maurer M; Casale TB; Saini SS; Ben-Shoshan M; Giménez-Arnau AM; Bernstein JA; Yagami A; Stjepanovic A; Radin A; Staudinger HW; Patel N; Amin N; Akinlade B; Fan C; Bauer D; Yancopoulos GD; Patel K; Mannent LP; Laws E
    J Allergy Clin Immunol; 2024 Jul; 154(1):184-194. PubMed ID: 38431226
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical experience of a chronic urticaria referral university center.
    Andrade Coelho Dias G; Cunha Coelho F; Filippo P; Lacerda Pedrazzi D; Nogueira Arraes AC; Perelló MI; Chigres Kuschnir F; Costa E
    Eur Ann Allergy Clin Immunol; 2020 May; 52(3):112-120. PubMed ID: 31287262
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.